weight loss drug
2025.06.05
2025.06.03
2025.05.26
2025.05.12
2025.05.08
2025.05.07
14:50
There are rumors that "WHO plans to include weight loss drugs in the list of essential medicines for the treatment of adult obesity for the first time". In response, the World Health Organization (WHO) said that since 2022, WHO has been developing a set of new guidelines on obesity prevention, care and treatment for different age groups (children, adolescents and adults). At present, the guidelines on the use of GLP-1 RA and GLP-1 RA/GIP dual receptor agonists to treat adult obese patients are being fully developed in accordance with the procedures of the Guidelines Review Committee, and the final plan is expected to be issued in August or September 2025. The purpose of the guidelines is to clarify the clinical indications, applications and planning considerations of GLP 1 RAs, including how and when such drugs can be used as part of a chronic disease management model that includes clinical interventions and lifestyle interventions. In addition, the above drugs are currently being reviewed by the WHO Expert Committee on the Selection and Use of Essential Medicines. The review process of this expert committee is independent of the guideline development process and aims to evaluate whether multiple drugs should be included in the WHO Model List of Essential Medicines (EML) and the WHO Model List of Essential Medicines for Children (EMLc). The two lists provide guidance to national or regional procurement agencies to help them select medicines that meet the priority health needs of the population. The measures mark a major shift in global public health policy in responding to the obesity epidemic.
2025.05.06
2025.05.01
2025.04.29
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
ASIA TECH WIRE

Grasp technology trends

Download